01-01-2024 | Adalimumab | Case report
Adalimumab/Duloxetine/Ustekinumab
Heart failure with reduced ejection fraction secondary to non-ischaemic dilated cardiomyopathy and loss of response
Published in: Reactions Weekly | Issue 1/2024
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event